{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:14:39Z","timestamp":1784067279274,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[2001,6]]},"DOI":"10.1378\/chest.119.6.1801","type":"journal-article","created":{"date-parts":[[2003,6,14]],"date-time":"2003-06-14T00:09:19Z","timestamp":1055549359000},"page":"1801-1806","source":"Crossref","is-referenced-by-count":41,"title":["Primary Pulmonary Hypertension In Israel"],"prefix":"10.1016","volume":"119","author":[{"given":"Liat","family":"Appelbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mordechai","family":"Yigla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniell","family":"Bendayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nira","family":"Reichart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gershon","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Priel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mordechai R.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.119.6.1801_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJM199701093360207","article-title":"Primary pulmonary hypertension","volume":"336","author":"Rubin","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.119.6.1801_bib2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","article-title":"Primary pulmonary hypertension: a national prospective study","volume":"107","author":"Rich","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.119.6.1801_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension: results of a national prospective registry","volume":"11","author":"D'alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.119.6.1801_bib4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.119.6.1801_bib5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0735-1097(97)00187-3","article-title":"PPH: improved long term effects and survival with continuous intravenous epoprostenol infusion","volume":"30","author":"Shapiro","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.119.6.1801_bib6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0002-8703(83)90288-0","article-title":"A reassessment of the effects of vasodilator drugs in primary pulmonary hypertension: guidelines for determining a pulmonary vasodilator response","volume":"105","author":"Rich","year":"1983","journal-title":"Am Heart J"},{"key":"10.1378\/chest.119.6.1801_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.76.1.135","article-title":"High dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy","volume":"76","author":"Rich","year":"1987","journal-title":"Circulation"},{"key":"10.1378\/chest.119.6.1801_bib8","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1378\/chest.95.6.1185","article-title":"Vasodilators in primary pulmonary hypertension: variability of long term response","volume":"95","author":"Dantzker","year":"1989","journal-title":"Chest"},{"key":"10.1378\/chest.119.6.1801_bib9","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1378\/chest.117.3.796","article-title":"Mortality from primary pulmonary hypertension in the United States 1979\u20131996","volume":"117","author":"Lillienfield","year":"2000","journal-title":"Chest"},{"key":"10.1378\/chest.119.6.1801_bib10","series-title":"Statistical methods for survival data analysis","author":"Lee","year":"1980"},{"key":"10.1378\/chest.119.6.1801_bib11","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1161\/01.CIR.89.4.1733","article-title":"Survival in PPH: validation of a prognostic equation","volume":"89","author":"Sandoval","year":"1994","journal-title":"Circulation"},{"key":"10.1378\/chest.119.6.1801_bib12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite suppressant drugs and the risk of primary pulmonary hypertension","volume":"335","author":"Abenhaim","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.119.6.1801_bib13","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1056\/NEJM199708283370904","article-title":"Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine","volume":"337","author":"Mark","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.119.6.1801_bib14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/01.RES.35.5.657","article-title":"Dietary pulmonary hypertension","volume":"35","author":"Fishman","year":"1974","journal-title":"Circ Res"},{"key":"10.1378\/chest.119.6.1801_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000203562","article-title":"Pulmonary hypertension in two patients with type I Gaucher disease while on alglucerase therapy","volume":"98","author":"Haratz","year":"1997","journal-title":"Acta Haematol"},{"key":"10.1378\/chest.119.6.1801_bib16","first-page":"194","article-title":"Familial PPH: clinical patterns","volume":"129","author":"Loyd","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.119.6.1801_bib17","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0140-6736(84)91452-1","article-title":"Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)","volume":"1","author":"Higenbottam","year":"1984","journal-title":"Lancet"},{"key":"10.1378\/chest.119.6.1801_bib18","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/hrt.57.3.270","article-title":"Treatment of primary pulmonary hypertension with intravenous epoprostenol","volume":"57","author":"Jones","year":"1987","journal-title":"Br Heart J"},{"key":"10.1378\/chest.119.6.1801_bib19","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/hrt.70.4.366","article-title":"Prostacyclin (epoprostenol) and heart-lung transplantation as treatment for severe pulmonary hypertension","volume":"70","author":"Higenbottam","year":"1993","journal-title":"Br Heart J"},{"key":"10.1378\/chest.119.6.1801_bib20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with contiguous intravenous prostacyclin (epoprostenol): results of a randomized trial","volume":"112","author":"Rubin","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.119.6.1801_bib21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","article-title":"Survival with primary pulmonary hypertension with long term continuous intravenous prostacyclin","volume":"121","author":"Barst","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.119.6.1801_bib22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215523295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215523295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T19:54:57Z","timestamp":1553111697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215523295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["S0012369215523295"],"URL":"https:\/\/doi.org\/10.1378\/chest.119.6.1801","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}